Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ramicirumab (Cyramza®) cannot be endorsed for use within NHS Wales in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. |
||
|
||
Medicine details |
||
| Medicine name | ramucirumab (Cyramza®) | |
| Formulation | 10 mg/ml concentrate for solution for infusion | |
| Reference number | 2628 | |
| Indication | For use in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 29/04/2016 | |
| Date of issue | 03/05/2016 | |